Nanoparticles in the clinic: An update

By A. Anselmo, S. Mitragotri. Bioengineering & Translational Medicine, 2019

1,310 citations recorded by the source corpus.

Abstract Nanoparticle drug delivery systems have been used in the clinic since the early 1990's. Since that time, the field of nanomedicine has evolved alongside growing technological needs to improve the delivery of various therapeutics. Over these past decades, newer generations of nanoparticles have emerged that are capable of performing additional delivery functions that can enable treatment via new therapeutic modalities. In the current clinical landscape, many of these new generation nanoparticles have reached clinical trials and have been approved for various indications. In the first issue of Bioengineering & Translational Medicine in 2016, we reviewed the history, current clinical landscape, and clinical challenges of nanoparticle delivery systems. Here, we provide a 3 year update on the current clinical landscape of nanoparticle drug delivery systems and highlight newly approved nanomedicines, provide a status update on previous clinical trials, and highlight new technologies that have recently entered the clinic.

Subfields: Biomaterials, Biomedical Engineering, Materials Chemistry

View Paper: https://www.semanticscholar.org/paper/4d4d0f153c2472247cffbde5f46ec083ea0e5756

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Lulu Cai
Rehmat Islam
Yangbao Miao
Yasir Waheed
Rongsheng Tong
Hongmei Liu
Yang Lei
Leming Sun

Citations in the corpus

Nanotechnology: A Revolution in Modern Industry (2023, background): “Specifically, the field of nanocomputers and linked devices help to control activation responses and their rates in mechanical procedures [2].”
Smart nanoparticles for cancer therapy (2023, background): “287 Therefore, the current clinical trials of smart nanoparticles for cancer diagnosis and treatment are also reviewed (Table 3).”